Search
- Net societal economic impact in Canada from withholding regulatory approval for generic OxyContin.
- Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in BC.
- Complexity and costs of assessing real-world effectiveness of new drugs.
- Drugs and the public cost of healthcare in Canada.
- Comparing access to new drugs in Canada's public and private sector drug plans. 2013 Annual Report.
- Medical devices and healthcare costs in Canada and 65 other countries 2006-2011.
- No link between faster drug approvals, regulatory safety warnings, drug withdrawals in Canada & USA.
- Potential costs from therapeutic substitution of proton pump inhibitor (PPI) drugs in Quebec.
- Les coûts potentiels découlant de la substitution thérapeutique des médicaments au Québec.
- Private insurance spending on drugs, dental and vision care in Canada, 1990 to 2010.
- Comparing access to new medicines by therapeutic class in public and private sector plans in Canada.
- Adverse drug reactions in Canada: facts v. urban myths.
- Spending on patented drugs in Canada. 2013 Annual Report.
- Challenging drug safety alarmism with facts.
- Private versus public drug coverage in Canada. 2014 Annual Report.
- Private health insurance costs in Canada.
- Canada's lagging healthcare productivity: Lost efficiencies and missed economic opportunities.
- Comparing access to new drugs in Canada's public drug plans. 2014 Annual Report.
- Do faster drug approvals increase safety risks? Evidence from Canada and Europe 2003-2012.
- Medical devices and healthcare costs in Canada and 66 other countries. 2014 Annual Report.
- Spending on Patented Drugs in Canada. 2014 Annual Report.
- OPINION - Pharma Funding for Patient Advocacy: Unethical or a Necessity?
- OPINION - Labour productivity is the key to healthcare sustainability - not rationing.
- OPINION - Cost is a phony excuse for denying patients access to new medicines.
- OPINION - Faster approval of new drugs does not compromise safety.
- Impact of improved data protection on health costs in Canada and Japan: lessons for the TPP.
- OPINION – Health-related benefits to flow from the Trans-Pacific Partnership (TPP).
- Are cost-effectiveness rules in public drug plans denying coverage to Canadians with rare disorders?
- Pharmacare: what are the costs for patients and taxpayers?
- Economic value of the utility-expansion for new cancer drugs approved in Canada from 2004 to 2014.
- Medical devices and health care costs in Canada and 71 other countries. 2015 Annual Report.
- Coverage for new medicines in Canada’s public drug plans, 2015.
- Including off-label drug indications in HTA jeopardizes patient health and discourages innovation
- Coverage for new medicines in public versus private drug plans in Canada.
- Spending on patented drugs in Canada 1990 to 2014.
- Pan-Canadian Pharmaceutical Alliance: another hurdle for Canadian patients to access new drugs?
- Economic cost of delayed access to 14 new cancer medicines in Canada’s public drug plans.
- How long do new patented medicines have market exclusivity in Canada’s public drug plans?
- Cost of physicians across Canada: 2016 Report
- Governments could save $5 billion annually by allowing user charges for physician services in Canada
- Les gouvernements pourraient économiser 5 milliards de dollars par année
- Fewer treatment options for patients if Canada adopts New Zealand's prescription drug policies.
- Economic evaluations in health technology assessments: what more can be done?
- Medical devices and health care costs in Canada and 74 other countries, 2010 to 2015
- Medical Resource Availability in Canada’s Provinces: 2016 Annual Report
- Medical Resource Availability in Canada and 34 OECD countries: 2016 Annual Report
- HTA decisions and access to mental health treatments in Canada’s public drug plans
- Hospital spending across Canada’s Provinces, 1990-2014
- Societal cost savings from abuse deterrent formulations for prescription opioids in Canada
- The fiscal burden of provincial government health spending across Canada
- Does Canada need a Patented Medicine Prices Review Board?
- Costs without benefits for patients? Non-medical spending in Canada’s public health system
- Facts about the cost of patented drugs in Canada
- Consequences of over-regulating the prices of new drugs in Canada
- Comparing expert representation on HTA advisory committees in Canada, the UK and Australia
- Prescription drug plan coverage 2016: how many Canadians were insured, under-insured or uninsured?
- Medical devices spending in Canada 2013-2017
- Coverage of new medicines in public versus private drug plans in Canada 2008-2017
- Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017
- Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate
- New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making
- Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?
- Facts about the cost of patented drugs in Canada: 2018 Edition.
- Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018.
- Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options.
- Evidence that innovative medicines improve health and economic outcomes: focused literature review.
- Medical Resources in Canada and OECD countries. 2019 Edition.
- HTA and public coverage of new mental health drugs in Quebec and Canada.
- Medical resources and spending across provincial healthcare systems in Canada.
- Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.
- Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall.
- Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018
- Coverage of new medicines in private versus public drug plans in Canada 2009-2018
- The costs of Immunoglobulin treatment in hospital and in the home in Quebec
- Preventive care of the future? Economic analysis of cardiovascular risk management.
- New pathways for U.S. importation threaten Canadian prescription drug supply.
- Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.
- New drug submissions in the United States and Canada 2014-2019: trends and policy implications.
- New Patented Medicine Regulations in Canada: Updated Case Study. (EN/FR)
- Nouvelle réglementation sur les médicaments brevetés au Canada: Étude de cas mise à jour.
- Patented Medicines Costs of Private Insurers: PMPRB Implications.
- Fewer new drug approvals in Canada: early indication of unintended consequences from new PMPRB regs?
- Clinical Trials in Canada Decrease: A Sign of Uncertainty Regarding Changes to the PMPRB?
- Did the PMPRB censor CHPI's Submission to its Draft Guidelines Consultation?
- A Socio-Psychological Perspective on Flattening the COVID-19 Curve.
- COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada.
- Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.
- Vaccines policy in Canada: International and Domestic Comparisons.
- Ensuring early access to a COVID-19 vaccine in Canada.
- Universal public funding for dental care in Canada: problems, policies, and politics.
- Career Options and Professional Integration of Internationally Trained Physicians in Canada.
- E-Mental Health Services and Unmet Needs of Canadians
- Canada’s Vaccine Development Capacity and the Federal Government’s Management of COVID-19
- Patented Medicines Expenditure in Canada 1990-2018
- Clinical Trials in Canada: Worrying Signs that PMPRB Changes will Impact Research Investment
- Health Technology Assessment Standards and Practices: How Does Canada Compare with Other Countries?
- National Strategy for Drugs for Rare Diseases should Prioritize Patients not Cost Containment
- Essais cliniques au Canada: des signes inquiétants que l'incertitude liée aux changements du CEPMB..
- Clinical Trials in Canada: Worrying Signs Remain Despite PMPRB’s Superficial Response
- Essais cliniques au Canada: signes inquiétants persistent malgré la réponse superficielle du CEPMB
